WO2007095057A3 - Use of eap protein for treating and preventing autoimmune neuroinflammatory diseases - Google Patents

Use of eap protein for treating and preventing autoimmune neuroinflammatory diseases Download PDF

Info

Publication number
WO2007095057A3
WO2007095057A3 PCT/US2007/003386 US2007003386W WO2007095057A3 WO 2007095057 A3 WO2007095057 A3 WO 2007095057A3 US 2007003386 W US2007003386 W US 2007003386W WO 2007095057 A3 WO2007095057 A3 WO 2007095057A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammal
eap
treating
autoimmune neuroinflammatory
agent
Prior art date
Application number
PCT/US2007/003386
Other languages
French (fr)
Other versions
WO2007095057A2 (en
Inventor
Triantafyllos Chavakis
Original Assignee
Us Gov Health & Human Serv
Triantafyllos Chavakis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Triantafyllos Chavakis filed Critical Us Gov Health & Human Serv
Publication of WO2007095057A2 publication Critical patent/WO2007095057A2/en
Publication of WO2007095057A3 publication Critical patent/WO2007095057A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a method of treating or preventing an autoimmune neuroinflammatory disease, e.g., multiple sclerosis, in a mammal. The method comprises administering to the mammal an Eap agent in an amount sufficient to treat or prevent the autoimmune neuroinflammatory disease. Also provided herein is a method of decreasing the infiltration of immune cells to the central nervous system in a mammal. The method comprises administering to the mammal an Eap agent in an amount effective to decrease the infiltration of immune cells to the central nervous system. Further provided herein is a method of inhibiting T cell-endothelial cell interactions in a mammal, comprising administering to the mammal an Eap agent in an amount effective to inhibit a T cell-endothelial cell interaction.
PCT/US2007/003386 2006-02-10 2007-02-08 Use of eap protein for treating and preventing autoimmune neuroinflammatory diseases WO2007095057A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77188406P 2006-02-10 2006-02-10
US60/771,884 2006-02-10

Publications (2)

Publication Number Publication Date
WO2007095057A2 WO2007095057A2 (en) 2007-08-23
WO2007095057A3 true WO2007095057A3 (en) 2007-11-01

Family

ID=38330507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/003386 WO2007095057A2 (en) 2006-02-10 2007-02-08 Use of eap protein for treating and preventing autoimmune neuroinflammatory diseases

Country Status (1)

Country Link
WO (1) WO2007095057A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9315554B2 (en) 2010-07-02 2016-04-19 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US9567379B2 (en) 2009-04-03 2017-02-14 The University Of Chicago Compositions and methods related to protein A (SpA) variants

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CN101951948B (en) 2007-08-31 2015-12-09 芝加哥大学 Ia method and composition is carried out with for staphylococcic pulmonary disease and disease
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
WO2002077010A2 (en) * 2001-01-10 2002-10-03 The Texas A & M University System Method of preventing t-cell mediated responses by map proteins
WO2003041726A1 (en) * 2001-11-16 2003-05-22 Biostapro Ab Use of an extracellular adherence protein for the manufacture of an anti-inflammatory drug

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
WO2002077010A2 (en) * 2001-01-10 2002-10-03 The Texas A & M University System Method of preventing t-cell mediated responses by map proteins
WO2003041726A1 (en) * 2001-11-16 2003-05-22 Biostapro Ab Use of an extracellular adherence protein for the manufacture of an anti-inflammatory drug

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARRAGHY N. ET AL.: "The adhesive and immunomodulating properties of the multifunctional staphylococcus aureus protein Eap.", MICROBIOLOGY, vol. 149, 2003, pages 2701 - 2707, XP002447471 *
XIE C. ET AL.: "Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus.", JEM, vol. 203, no. 4, 17 April 2006 (2006-04-17), pages 985 - 994, XP002447470 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567379B2 (en) 2009-04-03 2017-02-14 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US9315554B2 (en) 2010-07-02 2016-04-19 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides

Also Published As

Publication number Publication date
WO2007095057A2 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
WO2006039663A3 (en) Methods for the administration of iloperidone
WO2007095057A3 (en) Use of eap protein for treating and preventing autoimmune neuroinflammatory diseases
WO2007117996A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2005105107A3 (en) Hormone treatment of multiple sclerosis
WO2005123128A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
EP2331095A4 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2007053661A3 (en) Uses of anti-cd40 antibodies
WO2006035434A3 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
HK1105167A1 (en) Methods of treating type i diabetes by blocking vegf-mediated activity
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012064897A3 (en) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
WO2006078870A3 (en) Methods for treating adhesive capsulitis
WO2007014943A3 (en) Therapy for neurological diseases
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2006041835A3 (en) Methods of inhibiting cell death or inflammation in a mammal
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2007047205A3 (en) Enzyme inhibitors of pai-1
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
WO2009108706A3 (en) Methods for inhibiting six 1 and eya proteins
WO2011011706A3 (en) Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07750240

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07750240

Country of ref document: EP

Kind code of ref document: A2